title: Epoetin beta for the treatment of chemotherapy-induced anemia: an update.
abstract: Epoetin beta belongs to the class of erythropoiesis-stimulating agents (ESAs) that are currently available to treat anemic patients receiving chemotherapy. Chemotherapy-induced anemia affects a high percentage of cancer patients and, due to its negative effects on disease outcome and the patient's quality of life, should be treated when first diagnosed. Initial trials with ESAs have shown efficacy in improving quality of life and reducing the need for blood transfusions in patients with chemotherapy-induced anemia. However, recent meta-analyses have provided conflicting data on the impact of ESAs on survival and tumor progression. Here we provide an overview of these recent data and review the role of epoetin beta in the treatment of chemotherapy-induced anemia over the past 20 years.
authors.affiliation: Oncology Unit 2, University Hospital of Pisa, Pisa, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Galli
authors.affiliation: Primula Multimedia SRL, Pisa, Italy.
authors.forename: Clara
authors.initials: C
authors.lastname: Ricci
authors.affiliation: Primula Multimedia SRL, Pisa, Italy.
authors.forename: Colin Gerard
authors.initials: CG
authors.lastname: Egan
keywords: anemia; cancer; chemotherapy; epoetin beta; erythropoietin; treatment